{"mainPropery":{"diseaseId":7708,"diseaseName":"Subacute sclerosing panencephalitis","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7708/subacute-sclerosing-panencephalitis","synonyms":["SSPE","Dawson disease","Dawson Encephalitis"],"synonyms-with-source":[{"name":"SSPE"},{"name":"Dawson disease","source":"NORD"},{"name":"Dawson Encephalitis","source":"NORD"}],"identifiers":[{"identifierType":"OMIM","identifierId":"260470"},{"identifierType":"ORPHANET","identifierId":"2806"},{"identifierType":"UMLS","identifierId":"C0038522"}]},"diseaseCategories":[{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":364,"resourceName":"Encephalitis Society","abbreviation":"","address1":"32 Castlegate","address2":"Malton, North Yorkshire YO17 7DT","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"United Kingdom","phone":"+44 (0)1653 699599","tty":"","tollFree":"","fax":"","email":"support@encephalitis.info","url":"http://www.encephalitis.info/","freeText":"Social media:\r\nTwitter: @encephalitis\r\nFacebook: /encephalitissociety"}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/260470' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=Subacute%20sclerosing%20panencephalitis%5Btitle%5D%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Subacute sclerosing panencephalitis. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/185/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001419.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='https://www.ninds.nih.gov/Disorders/All-Disorders/Subacute-Sclerosing-Panencephalitis-Information-Page' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/966220-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022505' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2806' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1538,"resourceId":2169,"resourceName":"MeSH®","descriptionText":"<a href='http://www.nlm.nih.gov/cgi/mesh/2010/MB_cgi?mode=&index=12804' target='_blank'>MeSH®</a> (Medical Subject Headings) is a terminology tool used by the National Library of Medicine. Click on the link to view information on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1539,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ResearchTrials_ResearchProjects_Simple.php?lng=EN&LnkId=884&Typ=Pat' target='_blank'>Orphanet</a> lists European clinical trials, research studies, and patient registries enrolling people with this condition.&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1545,"resourceId":2173,"resourceName":"Merck Manual","descriptionText":"The <a href='http://www.merck.com/mmhe/sec23/ch273/ch273m.html' target='_blank'>Merck Manuals Online Medical Library</a> provides information on this condition for patients and caregivers.&nbsp;","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1548,"resourceId":2176,"resourceName":"Centers for Disease Control and Prevention","descriptionText":"You can obtain information on this topic from the <a href='http://www.cdc.gov/measles/about/complications.html' target='_blank'>Centers for Disease Control and Prevention</a> (CDC). The CDC is recognized as the lead federal agency for developing and applying disease prevention and control, environmental health, and health promotion and education activities designed to improve the health of the people of the United States.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:260470' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":10525,"questionText":"What is subacute sclerosing panencephalitis?","answerText":"<strong>Subacute sclerosing panencephalitis (SSPE)</strong> a rare condition that is caused by a measles infection acquired earlier in life. Signs and symptoms of the condition primarily affect the <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/002311.htm\" target=\"_blank\">central nervous system</a> and often develop approximately 7 to 10 years after a person recovers from the measles. Affected people may initially experience behavioral changes, <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000739.htm\" target=\"_blank\">dementia</a>, and disturbances in motor function. In the late stages of the disease, affected people often progress to a comatose state, and then to a persistent vegetative state. Ultimately, many people with SSPE succumb to fever, heart failure, or the brain's inability to continue controlling the <a href=\"https://www.nlm.nih.gov/medlineplus/autonomicnervoussystemdisorders.html\" target=\"_blank\">autonomic nervous system</a>.[11290][11291] It is unclear why some people develop SSPE after they have seemingly recovered from the measles while others do not. Researchers suspect that SSPE may be due to an abnormal immune response or a mutant form of the measles virus that causes a persistent infection within the central nervous system.[11290][11291][11300] Treatment is supportive and primarily based on the signs and symptoms present in each person. Recent studies have shown that certain medications (called antiviral  and immunomodulatory drugs) may slow the progression of the condition, although the best treatment regimen and their long-term effects in people with SSPE are currently unknown.[11291][11302]","dateModified":"2016-04-20T08:04:00"},"basicQuestions":[{"questionId":10518,"questionText":"What are the signs and symptoms of subacute sclerosing panencephalitis?","answerText":"Subacute sclerosing panencephalitis (SSPE) generally develops approximately seven to ten years after a person recovers from the measles. Early signs and symptoms of the condition can&nbsp;include behavioral changes and mild mental deterioration (affecting memory, thinking, language, and judgment). As the condition progresses, affected people may experience disturbances in motor function, such as an unsteady gait (style of walking) and myoclonic jerks (uncontrollable involuntary jerking movements of the head, trunk, or limbs). Some affected people may also become blind and/or develop seizures. The muscles of the leg can be very tense or lack tone, and some affected people experiencing  weakness and spasms in both legs. Because this can interfere with the ability to walk, people with SSPE may require devices to assist with mobility. In the late stages of the disease, affected people often progress to a comatose state, and then to a persistent vegetative state. Ultimately, many people with SSPE succumb to fever, heart failure, or the brain's inability to continue controlling the <a href=\"https://www.nlm.nih.gov/medlineplus/autonomicnervoussystemdisorders.html\" target=\"_blank\">autonomic nervous system</a>.[11290][11291]","dateModified":"2016-04-19T15:57:00","resourceClassificationName":"Symptoms","references":[{"referenceId":11290,"authors":"","articleTitle":"Subacute sclerosing panencephalitis","bookWebsiteJournalTitle":"MedlinePlus","date":"September 2014","volume":"","pages":"","url":"https://www.nlm.nih.gov/medlineplus/ency/article/001419.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11291,"authors":"","articleTitle":"NINDS Subacute Sclerosing Panencephalitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders and Stroke","date":"February 2016","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Subacute-Sclerosing-Panencephalitis-Information-Page","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10520,"questionText":"What causes subacute sclerosing panencephalitis?","answerText":"Subacute sclerosing panencephalitis (SSPE) is caused by a measles infection that is acquired earlier in life (often 7-10 years prior to the onset of SSPE symptoms). It is unclear why some people develop SSPE after they have seemingly recovered from the measles while others do not. Researchers suspect that SSPE may be due to an abnormal immune response or a mutant form of the measles virus that causes a persistent infection within the central nervous system (brain and spinal cord).[11290][11291][11300]<br />\r\n<br />\r\nAlthough the underlying cause of SSPE is poorly understood, several risk factors appear to be associated with the condition. SSPE affects males more often than females and is generally diagnosed in children and adolescents. The risk of developing SSPE may be higher for a person who gets measles before they are two years of age.[11290][11301]","dateModified":"2016-04-20T06:54:00","resourceClassificationName":"Cause","references":[{"referenceId":11290,"authors":"","articleTitle":"Subacute sclerosing panencephalitis","bookWebsiteJournalTitle":"MedlinePlus","date":"September 2014","volume":"","pages":"","url":"https://www.nlm.nih.gov/medlineplus/ency/article/001419.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11291,"authors":"","articleTitle":"NINDS Subacute Sclerosing Panencephalitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders and Stroke","date":"February 2016","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Subacute-Sclerosing-Panencephalitis-Information-Page","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11300,"authors":"Hayley Gans, MD; Yvonne A Maldonado, MD","articleTitle":"Clinical manifestations and diagnosis of measles","bookWebsiteJournalTitle":"UpToDate","date":"February 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11301,"authors":"","articleTitle":"Complications of Measles","bookWebsiteJournalTitle":"Centers for Disease Control and Prevention","date":"February 2015","volume":"","pages":"","url":"http://www.cdc.gov/measles/about/complications.html","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10521,"questionText":"How is subacute sclerosing panencephalitis diagnosed?","answerText":"A diagnosis of subacute sclerosing panencephalitis is often suspected based on the presence of characteristic <a href=\"https://rarediseases.info.nih.gov/gard/7708/subacute-sclerosing-panencephalitis/resources/9\" target=\"_blank\">signs and symptoms</a> in a person with a history of the measles. Additional testing can then be offered to confirm the diagnosis. This may include:[11290][11300]<br />\r\n<ul>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003931.htm\" id=\"anch_28\" target=\"_blank\">Electroencephalogram</a> (EEG)</li>\r\n    <li>Imaging studies, such as <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003791.htm\" target=\"_blank\">MRI</a> or <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003786.htm\" target=\"_blank\">CT scan</a></li>\r\n    <li>Serum <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003333.htm\" id=\"anch_30\" target=\"_blank\">antibody titer</a> to look for signs of previous measles infection</li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003428.htm\" target=\"_blank\">Spinal tap</a></li>\r\n</ul>","dateModified":"2016-04-20T07:08:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":11290,"authors":"","articleTitle":"Subacute sclerosing panencephalitis","bookWebsiteJournalTitle":"MedlinePlus","date":"September 2014","volume":"","pages":"","url":"https://www.nlm.nih.gov/medlineplus/ency/article/001419.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11300,"authors":"Hayley Gans, MD; Yvonne A Maldonado, MD","articleTitle":"Clinical manifestations and diagnosis of measles","bookWebsiteJournalTitle":"UpToDate","date":"February 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10522,"questionText":"How might subacute sclerosing panencephalitis be treated?","answerText":"Unfortunately, there is currently no cure for subacute sclerosing panencephalitis (SSPE). Treatment is supportive and primarily based on the signs and symptoms present in each person. For example, anticonvulsant and antispasmodic drugs may be given, as needed, to address some of the motor disturbances associated with the condition.[11291][11302]<br />\r\n<br />\r\nRecent studies have shown that certain medications (called antiviral  and immunomodulatory drugs) may slow the progression of the condition when given alone or in combination. Although these drugs can prolong life, the best treatment regimen and their long-term effects in people with SSPE are currently unknown.[11291][11302]","dateModified":"2016-04-20T07:19:00","resourceClassificationName":"Treatment","references":[{"referenceId":11291,"authors":"","articleTitle":"NINDS Subacute Sclerosing Panencephalitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders and Stroke","date":"February 2016","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Subacute-Sclerosing-Panencephalitis-Information-Page","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11302,"authors":"Häusler M, Aksoy A, Alber M, Altunbasak S, Angay A, Arsene OT, Craiu D, Hartmann H, Hiz-Kurul S, Ichiyama T, Iliescu C, Jocic-Jakubi B, Korinthenberg R, Köse G, Lukban MB, Ozkan M, Patcheva I, Teichler J, Vintan M, Yaramis A, Yarar C, Yis U, Yuksel D, Anlar B","articleTitle":"A Multinational Survey on Actual Diagnostics and Treatment of Subacute Sclerosing Panencephalitis","bookWebsiteJournalTitle":"Neuropediatrics","date":"December 2015","volume":"46(6)","pages":"377-384","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=26479761","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10523,"questionText":"What is the long-term outlook for people with s<span id=\"ctl00_MainContent_LabelDiseaseName\">ubacute sclerosing panencephalitis</span>?","answerText":"The long-term outlook (prognosis) for people with subacute sclerosing panencephalitis (SSPE) is poor. The condition is always fatal. Although most affected people die within one to three years, the average lifespan following diagnosis can vary. Studies show that a small group of people with SSPE will have a rapidly progressive form of the condition, leading to death within three months of diagnosis. Although rare, another small group will have a chronic, slowly progressive form that is associated with a relapsing and remitting course.[11291][11300]","dateModified":"2016-04-20T07:37:00","resourceClassificationName":"Prognosis","references":[{"referenceId":11291,"authors":"","articleTitle":"NINDS Subacute Sclerosing Panencephalitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders and Stroke","date":"February 2016","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Subacute-Sclerosing-Panencephalitis-Information-Page","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11300,"authors":"Hayley Gans, MD; Yvonne A Maldonado, MD","articleTitle":"Clinical manifestations and diagnosis of measles","bookWebsiteJournalTitle":"UpToDate","date":"February 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10524,"questionText":"How common is subacute sclerosing panencephalitis?","answerText":"In developed countries, subacute sclerosing panencephalitis (SSPE) is considered a rare disease. For example, fewer than 10 cases per year are reported in the United States. Furthermore, studies show that the number of SSPE cases diagnosed each year has declined by at least 90 percent in countries that have practiced widespread immunization with measles vaccine. The risk of having the condition is significantly higher in developing countries, such as India (over 20 cases per million people each year) and Eastern Europe.[11290][11291]<br />\r\n<br />\r\nSSPE affects males more often than females and is generally diagnosed in children and adolescents. The risk of developing SSPE may be higher for a person who gets measles before they are two years of age.[11290][11301]","dateModified":"2016-04-20T07:46:00","resourceClassificationName":"Statistics","references":[{"referenceId":11290,"authors":"","articleTitle":"Subacute sclerosing panencephalitis","bookWebsiteJournalTitle":"MedlinePlus","date":"September 2014","volume":"","pages":"","url":"https://www.nlm.nih.gov/medlineplus/ency/article/001419.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11291,"authors":"","articleTitle":"NINDS Subacute Sclerosing Panencephalitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders and Stroke","date":"February 2016","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Subacute-Sclerosing-Panencephalitis-Information-Page","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11301,"authors":"","articleTitle":"Complications of Measles","bookWebsiteJournalTitle":"Centers for Disease Control and Prevention","date":"February 2015","volume":"","pages":"","url":"http://www.cdc.gov/measles/about/complications.html","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":5158,"phenoTypeName":"Encephalitis","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Subacute_sclerosing_panencephalitis"}